Cadrenal Therapeutics, Common Stock Performance
| CVKD Stock | 14.99 0.98 7.00% |
Cadrenal Therapeutics, holds a performance score of 12 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 2.52, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cadrenal Therapeutics, will likely underperform. Use Cadrenal Therapeutics, treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside , to analyze future returns on Cadrenal Therapeutics,.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (7.67) | Five Day Return (13.28) | Year To Date Return 38.96 | Ten Year Return (77.61) | All Time Return (77.61) |
Last Split Factor 1:15 | Last Split Date 2024-08-20 |
1 | Disposition of 150000 shares by Jeff Cole of Cadrenal Therapeutics, at 0.94 subject to Rule 16b-3 | 09/10/2024 |
2 | Cadrenal Therapeutics Announces Sale of Common Stock Generating 5.1 Million in Gross Proceeds | 10/25/2024 |
3 | Acquisition by Wilson Glynn of 70000 shares of Cadrenal Therapeutics, at 0.94 subject to Rule 16b-3 | 11/05/2024 |
4 | Cadrenal Therapeutics reports Q3 results | 11/08/2024 |
5 | Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook | 11/19/2024 |
| Begin Period Cash Flow | 32.6 K | |
| Free Cash Flow | -3.5 M |
Cadrenal |
Cadrenal Therapeutics, Relative Risk vs. Return Landscape
If you would invest 790.00 in Cadrenal Therapeutics, Common on August 27, 2024 and sell it today you would earn a total of 709.00 from holding Cadrenal Therapeutics, Common or generate 89.75% return on investment over 90 days. Cadrenal Therapeutics, Common is currently generating 1.3247% in daily expected returns and assumes 8.2266% risk (volatility on return distribution) over the 90 days horizon. In different words, 73% of stocks are less volatile than Cadrenal, and 74% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cadrenal Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cadrenal Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cadrenal Therapeutics, Common, and traders can use it to determine the average amount a Cadrenal Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.161
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CVKD | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.23 actual daily | 73 73% of assets are less volatile |
Expected Return
| 1.32 actual daily | 26 74% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Cadrenal Therapeutics, is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cadrenal Therapeutics, by adding it to a well-diversified portfolio.
Cadrenal Therapeutics, Fundamentals Growth
Cadrenal Stock prices reflect investors' perceptions of the future prospects and financial health of Cadrenal Therapeutics,, and Cadrenal Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cadrenal Stock performance.
| Return On Equity | -1.25 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 20.5 M | ||||
| Shares Outstanding | 1.66 M | ||||
| Price To Book | 7.29 X | ||||
| EBITDA | (8.34 M) | ||||
| Net Income | (8.36 M) | ||||
| Total Debt | 21.35 K | ||||
| Book Value Per Share | 3.09 X | ||||
| Cash Flow From Operations | (3.53 M) | ||||
| Earnings Per Share | (6.73) X | ||||
| Market Capitalization | 24.86 M | ||||
| Total Asset | 8.52 M | ||||
| Retained Earnings | (15.07 M) | ||||
| Working Capital | 7.67 M | ||||
About Cadrenal Therapeutics, Performance
By analyzing Cadrenal Therapeutics,'s fundamental ratios, stakeholders can gain valuable insights into Cadrenal Therapeutics,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cadrenal Therapeutics, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cadrenal Therapeutics, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.98) | (1.03) | |
| Return On Capital Employed | (0.99) | (0.94) | |
| Return On Assets | (0.98) | (1.03) | |
| Return On Equity | (1.09) | (1.03) |
Things to note about Cadrenal Therapeutics, performance evaluation
Checking the ongoing alerts about Cadrenal Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cadrenal Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cadrenal Therapeutics, is way too risky over 90 days horizon | |
| Cadrenal Therapeutics, appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (8.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cadrenal Therapeutics, generates negative cash flow from operations | |
| Cadrenal Therapeutics, has a poor financial position based on the latest SEC disclosures | |
| About 34.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 150000 shares by Jeff Cole of Cadrenal Therapeutics, at 0.94 subject to Rule 16b-3 |
- Analyzing Cadrenal Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cadrenal Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Cadrenal Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cadrenal Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cadrenal Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cadrenal Therapeutics,'s stock. These opinions can provide insight into Cadrenal Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cadrenal Stock analysis
When running Cadrenal Therapeutics,'s price analysis, check to measure Cadrenal Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cadrenal Therapeutics, is operating at the current time. Most of Cadrenal Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Cadrenal Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cadrenal Therapeutics,'s price. Additionally, you may evaluate how the addition of Cadrenal Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |